Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Sponsor
He Eye Hospital
Study ID
NCT04601701
Status
Unknown

Conditions

  • Central Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab Ophthalmic and Intravitreal Dexamethasone. — DRUG
    Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
  • Bevacizumab Ophthalmic. — DRUG
    Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.

Study Details

The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO) in comparison to Bevacizumab (Avastin) alone.

Key Dates

First listed
Oct 26, 2020
Start date
Oct 17, 2020
Status verified
Oct 2020
Primary completion
Mar 30, 2021
Completion
Sep 17, 2021

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CRVO: Bevacizumab and intravitreal Dexamethasone.
    Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
  • Active Comparator: CRVO: Bevacizumab
    Participants with CRVO will receive a combination of Bevacizumab only.

Primary Outcome Measure

Mean change in monocular BCVA in the treatment eye [ Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. ]

Central Contacts